Pharmaceutical Technology
AUGUST 22, 2024
Packaging experts discuss emerging challenges in secondary packaging design for injectables that balance sustainability with end-user needs.
Bio Pharma Dive
AUGUST 22, 2024
The approval of both reformulated messenger RNA vaccines, which are designed to target the KP.2 virus strain, comes just ahead of the fall and winter seasons.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 22, 2024
Neurons aren’t the only brain cells producing the proteins associated with Alzheimer’s disease, a new study of mouse models reveals. It turns out that cells supporting neurons contribute to this process too. Amyloid beta proteins occur naturally in our brains, but have long, and now controversially, been associated with Alzheimer’s disease.
Pharmaceutical Technology
AUGUST 22, 2024
Leo Pharma spent $36m to acquire Timber Pharmaceuticals last year, along with its lead dermatology asset TMB-001.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 22, 2024
The Indian Council of Medical Research (ICMR) has announced a Request for Expressions of Interest (EoI) aimed at inviting researchers, academicians, and scientists to participate in the formulation of evidence-based guidelines for the empirical use of antibiotics in the management of sepsis, dental infections, and vaginal discharge.
Bio Pharma Dive
AUGUST 22, 2024
The FDA backed Jeff Shuren, the agency’s former CDRH leader, amid questions raised by The New York Times. Still, a spokesperson said the FDA has advised Shuren to take greater caution in managing recusal obligations.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
AUGUST 22, 2024
Borealis Biosciences launches with money from Novartis, which last year bought the biotech’s predecessor for a pair of drugs that treat a rare kidney disorder.
Pharma Times
AUGUST 22, 2024
The grant will support clinical trials of rare disease therapy for leukodystrophy
Bio Pharma Dive
AUGUST 22, 2024
Leqembi’s benefits are “too small to justify the significant cost to the NHS,” said the head of a UK agency in charge of determining medicine reimbursement.
Pharmaceutical Technology
AUGUST 22, 2024
Discover Avadel Pharmaceuticals' new patent for GHB formulations, enhancing narcolepsy treatment with a tailored dosage regimen for effective symptom relief.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioPharma Reporter
AUGUST 22, 2024
In the rapidly evolving field of drug discovery, Melanie Adams-Cioaba stands at the forefront, leading transformative advancements in cryo-electron microscopy (cryo-EM) at Thermo Fisher Scientific.
Pharmaceutical Technology
AUGUST 22, 2024
Discover Antisense Therapeutics' groundbreaking patent for treating muscular dystrophy, enhancing muscle function with a unique oligonucleotide method.
pharmaphorum
AUGUST 22, 2024
Discover how digital therapeutics (DTx) have evolved in the wake of COVID-19, and how they are changing the landscape of healthcare. Explore the fall and rise of DTx and their potential impact on patient care.
Pharmaceutical Technology
AUGUST 22, 2024
Discover Heidelberg Pharma AG's innovative patent enhancing CAR T-cell therapy for cancer and autoimmune diseases using anti-CD5 antibody drug conjugates for better outcomes.
BioPharma Reporter
AUGUST 22, 2024
ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients.
Pharmaceutical Technology
AUGUST 22, 2024
Discover Zydus Lifesciences' patented liquid sildenafil citrate formulation for treating pulmonary hypertension and erectile dysfunction, ensuring stability and effectiveness.
XTalks
AUGUST 22, 2024
The US Food and Drug Administration (FDA) has given the nod to Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC), a rare autoimmune disease that primarily affects women. PBC gradually destroys the bile ducts in the liver, leading to inflammation, scarring and, if untreated, potentially liver failure. For the 130,000 Americans living with this condition, many find existing treatments either ineffective or hard to tolerate.
Pharmaceutical Technology
AUGUST 22, 2024
Despite its marketing approval, Leqembi’s cost effectiveness falls short of NICE’s standards to justify wide range use in the UK.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
AUGUST 22, 2024
BioMarin names Amgen's Greg Friberg to lead its R&D and former Roche exec James Sabry as its chief dealmaker amid a strategy change
Pharmaceutical Technology
AUGUST 22, 2024
A US FDA advisory committee (AdComm) is set to evaluate Zynquista as an adjunct therapy for type 1 diabetes and chronic kidney disease (CKD).
Outsourcing Pharma
AUGUST 22, 2024
H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harness the power of global healthcare networks to provide humanitarian aid in regions that need it most.
Pharmaceutical Technology
AUGUST 22, 2024
Touchlight collaborated with the University of Nottingham to supply GMP-grade dbDNA tech to develop next-gen vaccine for the Zika virus.
Fierce Pharma
AUGUST 22, 2024
The FDA is once again gathering external experts to scrutinize PD-1 inhibitors as a group. | The FDA will hold an advisory committee meeting on Sept. 26 to consider whether approvals for checkpoint inhibitors in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma—as well as in esophageal squamous cell carcinoma (ESCC)—should be restricted based on a tumor’s PD-L1 expression.
Pharmaceutical Technology
AUGUST 22, 2024
CTI Clinical Trial & Consulting Services and Crown Bioscience have announced a strategic partnership to boost oncology drug development.
Pharmaceutical Commerce
AUGUST 22, 2024
In the final part of his Pharma Commerce video interview, Matt Hawkins, CaryHealth’s Chief Technology Officer, comments on the importance of mitigating security risks, along with ways to take action.
Pharmaceutical Technology
AUGUST 22, 2024
The FDA) has accepted the sBLA filed by BMS for Opdivo (nivolumab) and Yervoy (ipilimumab) to treat unresectable hepatocellular carcinoma.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Commerce
AUGUST 22, 2024
The unveiling of the microbial fermentation manufacturing plant is headlined by a $131 million financial commitment.
Pharmaceutical Technology
AUGUST 22, 2024
China's National Medical Products Administration (NMPA) has granted approval for Innovent Biologics’ Kristen rat sarcoma (KRAS) G12C inhibitor, Dupert (fulzerasib), to treat advanced non-small cell lung cancer (NSCLC) in adults.
pharmaphorum
AUGUST 22, 2024
BMS looks ahead to April verdict from FDA on Opdivo/Yervoy combination as first-line treatment for unresectable hepatocellular carcinoma.
Pharmaceutical Commerce
AUGUST 22, 2024
The latest news for pharma industry insiders.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
246 
Let's personalize your content